177O Lenvatinib plus pembrolizumab versus treatment of physician’s choice in patients with previously treated advanced endometrial cancer: Study 309/KEYNOTE-775 Asian subgroup

K. Yonemori, K. Fujiwara, K. Hasegawa, M. Yunokawa, K. Ushijima, S. Suzuki, A. Shikama, S. Minobe, T. Usami,J-W. Kim,B-G. Kim,P-H. Wang,T-C. Chang, K. Yamamoto, S. Han, J. McKenzie, G. Barresi, T. Miura,V. Makker, Y.M. Kim

Annals of Oncology（2022）

引用 0|浏览2

暂无评分

摘要

In the global phase 3 Study 309/KEYNOTE-775 (NCT03517449), lenvatinib (len) + pembrolizumab (pembro) significantly improved PFS and OS vs treatment of physician’s choice chemotherapy (TPC) in patients (pts) with previously treated advanced endometrial cancer (EC). We present outcomes for the Asian subgroup from Study 309/KEYNOTE-775 at the time of final prespecified efficacy analysis.

查看译文

关键词

advanced endometrial cancer,endometrial cancer,pembrolizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要